Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Bolesław Rutkowski"'
Autor:
Bolesław Rutkowski, Julian Swierczynski, Joanna Blaszak, Elzbieta Sucajtys-Szulc, Marek Szolkiewicz, Marcin Konarzewski, Sławomir Lizakowski
Publikováno v:
American Journal of Nephrology. 40:157-163
Background: A high level of circulating PCSK9 binds to the LDL receptor, reduces its cell's surface density and leads to hypercholesterolemia. The aim of this study was to examine the circulating PCSK9 level in patients with kidney disease. Methods:
Autor:
Andrzej Wiecek, Sławomir Lizakowski, Władysław Sułowicz, Stanisław Czekalski, Radosław Szubert, Ewa Król, Bolesław Rutkowski, Piotr Czarniak, Ewa Kraszewska
Publikováno v:
American Journal of Nephrology. 29:264-273
Background: Continuous increase in the number of patients with end-stage renal disease demands early detection of chronic kidney disease (CKD). The aim of the present study was to diagnose CKD in its earliest stages in a randomly selected population
Autor:
Bolesław Rutkowski, Grażyna Odrowąż-Sypniewska, Wiesława Łysiak-Szydłowska, Beata Sulikowska, Jacek Manitius
Publikováno v:
American Journal of Nephrology. 28:391-396
Background/Aim: It is unknown to what extent uric acid (UA) may affect vessel function and participate in tubulointerstitial damage. We examined the relationship between intrarenal vessel function and serum UA and its excretion in association with ur
Autor:
Beata Sulikowska, Bolesław Rutkowski, Wieslawa Lysiak-Szydlowska, Tomasz Nieweglowski, Jacek Manitius
Publikováno v:
American Journal of Nephrology. 24:474-482
Background: ω–3 polyunsaturated acids therapy is efficient in primary IgA nephropathy. It is unknown whether doses of ω–3 smaller than those given previously are still effective. The aim of the study was to examine the effect of ω–3 therapy
Autor:
Bolesław Rutkowski, Wieslawa Lysiak-Szydlowska, Zbigniew Zdrojewski, Barbara Kortas, Ewa Kisielnicka, Małgorzata Wróblewska
Publikováno v:
American journal of nephrology. 20(5)
Though it is said that some immunosuppressive agents are implicated in the development of hyperlipidemia in kidney recipients, this subject is still controversial. Main plasma lipid parameters, as well as apolipoproteins A1 and B were measured period